Atlas Trials

A Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeat Doses of Inhaled ETD001 in People With Cystic Fibrosis

Clinical trial NCT06478706 · COMPLETED

Trial details

NCT number
NCT06478706
Sponsor
Enterprise Therapeutics Ltd
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Cystic Fibrosis
Start date
2024-06-26
Primary completion
2025-11-14
Enrollment
57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.